SAR302503

This page shows the latest SAR302503 news and features for those working in and with pharma, biotech and healthcare.

Jakafi cleared for bone marrow disorder by FDA

pacritinib. Sanofi was forced to discontinue development of its fedratinib (SAR302503) candidate after cases of a rare form of encephalopathy were seen in late-stage trials.

Latest news

Sanofi pulls development of blood cancer drug

The France-based pharma company said the reason to pull fedratinib – also known as SAR302503 – was due to the drug's link to an increased risk of the brain disorder
Jakavi shows long-term survival benefit in myelofibrosis

Meanwhile, Jakavi will have the market to itself for at least as a couple of years, as rival JAK inhibitors such as Sanofi's SAR302503 and Gilead Sciences' CYT387 are still
Sanofi plans to file JAK2 inhibitor after positive phase III

Aiming for approval in blood cancer myelofibrosis. Sanofi has started to prepare for regulatory filings of its blood cancer treatment SAR302503 following positive results in a pivotal study. ... In the trial, patients with intermediate-2 or high-risk
Sanofi has 65 new compounds in development, says R&D chief

Elias Zerhouni to showcase pharma company's pipeline, promises costs will be rigorously managed

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

Pharma deals during November 2013

While Sanofi announced this month that it had discontinued clinical trials of fedratinib (SAR302503), an investigational JAK2 inhibitor, Baxter entered an exclusive global agreement (headline value $172m) to develop and commercialise

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Medical Writer: Salary TBC

Senior Medical Writer: Up to £50, 000 with Benefits

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Senior Planner – Healthcare Advertising – New Role: Salary TBC

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Account Director, Medical Education: Salary TBC

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Senior Medical Writer: Great salary and benefits

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

Digital Account Director: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Account Director, Healthcare Marketing Agency: Salary TBC

Project Manager/ Account Manager: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

International Childhood Cancer Day 2019: The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues: Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups: A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...